Novo Nordisk Ramps Up Defense on Two Continents as Competitive Threats Intensify
Published on 07/08/2026 at 14:09 | Redaktion boerse-global.de
Novo Nordisk is racing to contain market share erosion on multiple fronts, restructuring its South Korean operations while simultaneously forging a partnership for a long-acting obesity implant. The moves come as the Danish drugmaker confronts an increasingly aggressive Eli Lilly and a newly constrained pricing environment in the United States.
In Asia, the numbers paint a stark picture. Eli Lilly’s Mounjaro rang up 323 billion won in South Korean sales earlier this year, dwarfing the 104 billion won generated by Novo Nordisk’s Wegovy. To stem the bleeding, Novo Nordisk slashed Wegovy’s wholesale price by roughly 40%. The discount failed to halt the slide—Eli Lilly last month added high-dose versions of Mounjaro to the Korean market. In response, the company has merged its diabetes and obesity divisions in the country and installed a new medical lead to oversee clinical trials and regulatory processes, hoping shorter decision lines can slow the rival’s momentum.
The trouble in South Korea mirrors a global pattern. In the United States, Eli Lilly’s Zepbound has overtaken Wegovy in weekly prescriptions. That worldwide pressure prompted a leadership shakeup last year, with Mike Doustdar replacing longtime CEO Lars Fruergaard Jorgensen. A subsequent restructuring eliminated 9,000 positions, or about 11% of the workforce.
On the product front, Novo Nordisk is looking ahead with a new alliance. The company will work with Vivani Medical to develop NPM-139, a semaglutide implant designed to deliver a consistent dose once or twice a year. A Phase 1 trial comparing the implant directly with Wegovy injections is scheduled to begin in mid-2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Yet even as the pipeline develops, the U.S. market is imposing new constraints. Since July 1, 2026, the Medicare Bridge Program has capped seniors’ monthly out-of-pocket cost for GLP-1 drugs like Wegovy at $50, with the government purchase price fixed at $245. The program guarantees volume but locks Novo Nordisk into a rigid pricing framework.
That price pressure is already weighing on the outlook. Doustdar warned in February that earnings could fall as much as 13% this year, driven by planned rebates. Starting January 2027, Wegovy’s price is slated to drop by roughly half, while Ozempic will be 35% cheaper. The warnings have rattled Wall Street—analysts downgraded the stock to Hold in early July, and prominent investor Terry Smith liquidated his entire position, calling the company an “investment disaster.”
The stock has shown resilience in recent weeks, closing Tuesday at €43.43, up nearly 22% over the past month. On Wednesday, however, it slipped about 2% to €42.58 as the restructuring news landed. The rally has pushed the Relative Strength Index to 68.9, signaling overbought territory, though the shares remain above both their 50-day and 200-day moving averages. Year to date, the stock is still down roughly 27%, far from the 52-week high of €61.20.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
All eyes now turn to August 5, 2026, when Novo Nordisk reports its next quarterly results. Investors will be looking for concrete numbers on margin erosion and, critically, the trajectory of the oral Wegovy tablet, which captured 65% of new U.S. prescriptions in the previous quarter. Whether that momentum can offset the mounting headwinds from price cuts and competitive pressure will determine if this month’s recovery has legs—or is merely a pause in a longer slide.
Ad
Novo Nordisk Stock: New Analysis - 8 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
